13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
75 檔
26.0%
At the close of Q1 2026, Blue Owl Capital Holdings LP disclosed equity holdings valued at approximately $664.5M, spread across 75 reported holdings.
Blue Owl Capital Holdings LP executed strategic sector rebalancing during Q1 2026, establishing 20 new positions while fully exiting 25 holdings and trimming 16 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AKTS | Aktis Oncology Inc | Stock-Other | 15.20% | -0.31% | — | |
| 2 | LRMR | Larimar Therapeutics Inc | Stock-Other | 8.61% | -4.40% | +4.34% | |
| 3 | ✓ | Engene Holdings Inc | Stock-Other | 8.08% | -8.08% | EXIT | |
| 4 | NCDL | Nuveen Churchill Direct Lend | Stock-Other | 7.33% | -3.32% | — | |
| 5 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 7.29% | -3.07% | -18.77% | |
| 6 | OBDC | Blue Owl Capital CORP | Stock-Financials | 6.08% | -2.73% | — | |
| 7 | MPLT | Maplight Therapeutics Inc | Stock-Other | 5.49% | -1.55% | +207.57% | |
| 8 | CMPX | Compass Therapeutics Inc | Stock-Other | 4.18% | -2.99% | -15.14% | |
| 9 | CNTX | Context Therapeutics Inc | Stock-Other | 3.58% | -3.34% | -31.53% | |
| 10 | HLLY | Holley Inc | Stock-Other | 3.49% | -1.81% | +2.18% | |
| 11 | EYPT | Eyepoint Inc | Stock-Other | 3.16% | -1.52% | +132.45% | |
| 12 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 2.14% | -0.77% | — | |
| 13 | CNDT | Conduent Inc | Stock-Other | 1.73% | -0.62% | +4.44% | |
| 14 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.70% | -0.78% | +42.33% | |
| 15 | AQST | Aquestive Therapeutics Inc | Stock-Other | 1.50% | -0.91% | +156.75% | |
| 16 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.44% | -0.41% | — | |
| 17 | ✓ | Compass Pathways PLC | Stock-Other | 1.38% | -0.60% | — | |
| 18 | IMMX | Immix Biopharma Inc | Stock-Other | 1.34% | -0.66% | -44.48% | |
| 19 | IMA | Imagenebio Inc | Stock-Other | 1.29% | -0.48% | +16.45% | |
| 20 | CVEO | Civeo CORP | Stock-Other | 1.28% | -1.28% | EXIT | |
| 21 | LENZ | Lenz Therapeutics Inc | Stock-Other | 1.25% | -0.60% | +237.81% | |
| 22 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.18% | -0.84% | -26.43% | |
| 23 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.16% | -1.16% | EXIT | |
| 24 | OVID | Ovid Therapeutics Inc | Stock-Other | 1.14% | -1.14% | EXIT | |
| 25 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.05% | -0.22% | -22.36% | |
| 26 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.01% | -1.01% | EXIT | |
| 27 | STWD | Starwood Property Trust Inc | Stock-Real Estate | 0.73% | -0.25% | — | |
| 28 | ✓ | Adc Therapeutics SA | Stock-Other | 0.70% | -0.58% | — | |
| 29 | EVMN | Evommune Inc | Stock-Other | 0.62% | -0.26% | — | |
| 30 | DELL | Dell Technologies -c | Stock-Tech | 0.61% | +1.53% | -74.19% | |
| 31 | ✓ | Larimar Therapeutics Inc | Stock-Other | 0.51% | -0.49% | — | |
| 32 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.51% | +0.14% | -70.87% | |
| 33 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 0.47% | +1.00% | -73.16% | |
| 34 | WW | Ww International Inc-new | Stock-Other | 0.35% | -0.15% | — | |
| 35 | ✓ | Engene Holdings Inc | Stock-Other | 0.35% | -0.35% | EXIT | |
| 36 | EPD | Enterprise Products Partners | Stock-Energy | 0.32% | -0.32% | EXIT | |
| 37 | FLD | Fold Holdings Inc | Stock-Other | 0.30% | -0.24% | — | |
| 38 | OPTXW | Omnilit Acquisition Cl A -23 | Stock-Other | 0.23% | -0.23% | EXIT | |
| 39 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.19% | -0.07% | — | |
| 40 | ✓ | Mineralys Therapeutics Inc | Stock-Other | 0.16% | -0.16% | EXIT | |
| 41 | NIOBW | Niocorp Developments LTD -28 | Stock-Other | 0.14% | -0.08% | -63.47% | |
| 42 | ✓ | Compass Therapeutics Inc | Stock-Other | 0.13% | -0.11% | — | |
| 43 | BNAIW | Brand Engagement Netwo -cw27 | Stock-Other | 0.11% | -0.08% | -38.86% | |
| 44 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.10% | -0.10% | EXIT | |
| 45 | ✓ | Rezolve Ai LTD | Stock-Other | 0.05% | -0.02% | -18.73% | |
| 46 | PIPR | Piper Sandler Cos | Stock-Financials | 0.05% | -0.02% | — | |
| 47 | ✓ | Alpha Modus Hldgs Inc | Stock-Other | 0.04% | -0.04% | EXIT | |
| 48 | ET | Energy Transfer LP | Stock-Energy | 0.03% | -0.01% | — | |
| 49 | ✓ | Stock-Other | 0.03% | -0.03% | EXIT | ||
| 50 | CAI | Caris Life Sciences Inc | Stock-Other | 0.02% | -0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MPLT | Maplight Therapeutics Inc | +3.7% | +207.57% | Add |
| 2 | EYPT | Eyepoint Inc | +1% | +132.45% | Add |
| 3 | LRMR | Larimar Therapeutics Inc | +0.6% | +4.34% | Add |
| 4 | LENZ | Lenz Therapeutics Inc | +0.5% | +237.81% | Add |
| 5 | AQST | Aquestive Therapeutics Inc | +0.5% | +156.75% | Add |
| 6 | ✓ | Engene Holdings Inc | +0.3% | +1316.00% | Add |
| 7 | ELDN | Eledon Pharmaceuticals Inc | +0.3% | -26.43% | Trim |
| 8 | CNTX | Context Therapeutics Inc | +0.2% | -31.53% | Trim |
| 9 | RARE | Ultragenyx Pharmaceutical In | +0.2% | +42.33% | Add |
| 10 | OPTXW | Omnilit Acquisition Cl A -23 | +0.2% | — | Unchanged |
| 11 | BNAIW | Brand Engagement Netwo -cw27 | +0.1% | -38.86% | Trim |
| 12 | EPD | Enterprise Products Partners | 0% | — | Unchanged |
| 13 | FLD | Fold Holdings Inc | — | — | Unchanged |
| 14 | SHFS | Shf Holdings Inc | — | — | Unchanged |
| 15 | ✓ | Pagaya Technologies LTD | — | — | Unchanged |
| 16 | AEON | Aeon Biopharma Inc | — | -2.40% | Trim |
| 17 | BTMWQ | Bitcoin Depot Inc-cw23 | — | — | Unchanged |
| 18 | ✓ | — | — | Unchanged | |
| 19 | TVGNW | Semper Paratus Acqu -cw26 | — | — | Unchanged |
| 20 | XBPEW | Cf Acquisition Viii A -cw27 | — | — | Unchanged |
| 21 | SDSTW | Global Partner Acq A -cw27 | — | -47.37% | Trim |
| 22 | LIMNW | Liminatus Pharma Inc-cl A-28 | — | — | Unchanged |
| 23 | ASBPW | Aspire Biopharma Holdin-cw27 | — | — | Unchanged |
| 24 | ✓ | Katapult Holdings Inc | — | — | Unchanged |
| 25 | ✓ | Waldencast PLC | — | — | Unchanged |
| 26 | SLND-WS | Legato Merger CORP Ii -cw23 | 0% | — | Unchanged |
| 27 | ✓ | Blue Gold LTD | 0% | — | Unchanged |
| 28 | ✓ | Roadzen Inc | 0% | — | Unchanged |
| 29 | DAVEW | Dave Inc -cw27 | 0% | — | Unchanged |
| 30 | AMODW | Insight Acquisition Co -cw23 | 0% | — | Unchanged |
| 31 | DAICW | Cid Holdco Inc -26 | 0% | +48.17% | Add |
| 32 | CAH | Cardinal Health Inc | 0% | — | Unchanged |
| 33 | BKSY-WS | Blacksky Technology -cw24 | 0% | — | Unchanged |
| 34 | ✓ | Rezolve Ai LTD | 0% | -18.73% | Trim |
| 35 | ✓ | Alpha Modus Hldgs Inc | 0% | — | Unchanged |
| 36 | ✓ | -0.1% | — | Unchanged | |
| 37 | MRKR | Marker Therapeutics Inc | -0.1% | — | Unchanged |
| 38 | PLRX | Pliant Therapeutics Inc | -0.1% | — | Unchanged |
| 39 | ✓ | Adc Therapeutics SA | -0.2% | — | Unchanged |
| 40 | CGEM | Cullinan Therapeutics Inc | -0.2% | -18.77% | Trim |
| 41 | PVLA | Palvella Therapeutics Inc | -0.3% | -22.36% | Trim |
| 42 | IMMX | Immix Biopharma Inc | -0.3% | -44.48% | Trim |
| 43 | NIOBW | Niocorp Developments LTD -28 | -0.4% | -63.47% | Trim |
| 44 | IMA | Imagenebio Inc | -0.5% | +16.45% | Add |
| 45 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.6% | -40.28% | Trim |
| 46 | ORIC | Oric Pharmaceuticals Inc | -0.8% | -70.87% | Trim |
| 47 | CNDT | Conduent Inc | -1.1% | +4.44% | Add |
| 48 | ✓ | Engene Holdings Inc | -1.3% | +31.40% | Add |
| 49 | CVEO | Civeo CORP | -1.3% | -51.29% | Trim |
| 50 | DELL | Dell Technologies -c | -1.5% | -74.19% | Trim |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 75 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AKTS, LRMR, ENGENE HOLDINGS INC) accounted for 26.0% of total reported equity market value during Q1 2026.
Top New Position Initiated
AKTS
市值: $56.6M
Top Position Liquidated / Trimmed
RPTX
前期市值: $9.0M
During Q1 2026, Blue Owl Capital Holdings LP's top holdings by market value included AKTS (15.2%)、LRMR (8.6%)、ENGENE HOLDINGS INC (8.1%). The largest single position, AKTS, represented 15.2% of total portfolio value.
In Q1 2026, Blue Owl Capital Holdings LP made 73 total portfolio adjustments, initiating 20 new buys, adding to 12 positions, trimming 16 holdings, and fully liquidating 25 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.